A Randomized, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Status: Recruiting
Location: See all (13) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Primary Uveal Melanoma, classified as high-risk of relapse (AJCC Stage II or Stage 3)
• Completed primary local therapy (enucleation, proton beam therapy, plaque brachytherapy)
• ECOG performance status of 0 or 1
• Adequate organ function
• Age 18 or older
• Written informed consent and ability to comply
• Primary local therapy completed within 120 days before C1D1/randomization.
• Contraception requirements
Locations
United States
Arizona
Honor Health Research Institute
RECRUITING
Scottsdale
California
UCLA Medical Center
NOT_YET_RECRUITING
Los Angeles
Massachusetts
Dana Farber Cancer Institute
NOT_YET_RECRUITING
Boston
Michigan
Cancer Hematology Centers Western Michigan
NOT_YET_RECRUITING
Grand Rapids
North Carolina
Duke Cancer Center
NOT_YET_RECRUITING
Raleigh
New York
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITING
New York
Northwell Health
NOT_YET_RECRUITING
New York
Ohio
Cleveland Clinic
NOT_YET_RECRUITING
Cleveland
Pennsylvania
Wills Eye Hospital at Thomas Jefferson University
RECRUITING
Philadelphia
Tennessee
Sarah Cannon Research Institute (SCRI)
RECRUITING
Nashville
Wisconsin
University of Wisconsin Health
NOT_YET_RECRUITING
Madison
Other Locations
Canada
Universite de Montreal - Centre de Recherche du Centre Hospitalier de l'Universite de Montreal
NOT_YET_RECRUITING
Montréal
Princess Margaret Cancer Centre
RECRUITING
Toronto
Contact Information
Primary
IDEAYA Clinical Trials
IDEAYAClinicalTrials@ideayabio.com
+1-855-433-2246
Backup
Holger Thurm
hthurm@ideayabio.com
Time Frame
Start Date: 2026-09
Estimated Completion Date: 2034-04
Participants
Target number of participants: 450
Treatments
Experimental: Treatment
Participant Group/Arm: Treatment combination dose of IDE196 + crizotinib will be tested
No_intervention: Observation
Participant Group/Arm: Observation Standard of care observation \& follow-up (no treatment)
Related Therapeutic Areas
Sponsors
Leads: IDEAYA Biosciences